NNVC

Company Overview — What Does NANOVIRICIDES, INC. Do?

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut. NANOVIRICIDES, INC. (NNVC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Anil R. Diwan and employs approximately 20 people, headquartered in Reno, Connecticut. With a market capitalization of $21M, NNVC is one of the notable companies in the Healthcare sector.

NANOVIRICIDES, INC. (NNVC) Stock Rating — Reduce (April 2026)

As of April 2026, NANOVIRICIDES, INC. receives a Reduce rating with a composite score of 27.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NNVC ranks #3,776 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NANOVIRICIDES, INC. ranks #633 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NNVC Stock Price and 52-Week Range

NANOVIRICIDES, INC. (NNVC) currently trades at $0.98. The stock lost $0.08 (7.3%) in the most recent trading session. The 52-week high for NNVC is $2.23, which means the stock is currently trading -55.9% from its annual peak. The 52-week low is $0.85, putting the stock 15.6% above its annual trough. Recent trading volume was 128K shares, suggesting relatively thin trading activity.

Is NNVC Overvalued or Undervalued? — Valuation Analysis

NANOVIRICIDES, INC. (NNVC) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.11x, versus the sector average of 2.75x.

At current multiples, NANOVIRICIDES, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

NANOVIRICIDES, INC. Profitability — ROE, Margins, and Quality Score

NANOVIRICIDES, INC. (NNVC) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -84.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -76.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NNVC Debt, Balance Sheet, and Financial Health

NANOVIRICIDES, INC. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.43x, indicating strong short-term liquidity.

NNVC has a beta of 0.98, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NANOVIRICIDES, INC. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NANOVIRICIDES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NANOVIRICIDES, INC. reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-9M. Operating income came in at $-9M.

In Q2 2026, NANOVIRICIDES, INC. reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q1 2026, NANOVIRICIDES, INC. reported revenue of $0 and earnings per share (EPS) of $-0.10. Net income for the quarter was $-2M. Operating income came in at $-2M.

In FY 2025, NANOVIRICIDES, INC. reported revenue of $0 and earnings per share (EPS) of $-0.63. Net income for the quarter was $-9M. Operating income came in at $-10M.

Over the past 8 quarters, NANOVIRICIDES, INC. has experienced revenue contraction from $0 to $0. Investors analyzing NNVC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NNVC Dividend Yield and Income Analysis

NANOVIRICIDES, INC. (NNVC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NNVC Momentum and Technical Analysis Profile

NANOVIRICIDES, INC. (NNVC) has a momentum factor score of 23/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

NNVC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NANOVIRICIDES, INC. (NNVC) ranks #633 out of 838 stocks based on the Blank Capital composite score. This places NNVC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NNVC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NNVC vs S&P 500 (SPY) comparison to assess how NANOVIRICIDES, INC. stacks up against the broader market across all factor dimensions.

NNVC Next Earnings Date

No upcoming earnings date has been announced for NANOVIRICIDES, INC. (NNVC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NNVC? — Investment Thesis Summary

The quantitative profile for NANOVIRICIDES, INC. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 23/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, NANOVIRICIDES, INC. (NNVC) earns a Reduce rating with a composite score of 27.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NNVC stock.

Related Resources for NNVC Investors

Explore more research and tools: NNVC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NNVC head-to-head with peers: NNVC vs AZN, NNVC vs SLGL, NNVC vs VMD.